Heron Therapeutics
(HRTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,015 | 5,736 | 7,562 | 7,593 | 1,569 |
| Marketable Securities | N/A | N/A | N/A | N/A | 39 |
| Receivables | 614 | 356 | 224 | 171 | 486 |
| TOTAL | $3,629 | $6,400 | $8,222 | $8,313 | $2,313 |
| Non-Current Assets | |||||
| PPE Net | 407 | 399 | 455 | 510 | 596 |
| Other Non-Current Assets | 53 | 53 | 128 | 128 | 128 |
| TOTAL | $460 | $452 | $583 | $638 | $724 |
| Total Assets | $4,089 | $6,852 | $8,805 | $8,951 | $3,037 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 157 | 128 | 241 | 162 | 231 |
| Accrued Expenses | 1,117 | 2,410 | 1,626 | 1,633 | 1,953 |
| TOTAL | $1,369 | $2,650 | $1,982 | $1,887 | $2,404 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 95 | 112 | 115 | 92 | 220 |
| TOTAL | $189 | $196 | $228 | $268 | $151 |
| Total Liabilities | $1,558 | $2,846 | $2,210 | $2,155 | $2,555 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,006 | 2,006 | 1,976 | 1,971 | 1,969 |
| Common Shares | 401 | 401 | 395 | 394 | 139,650 |
| Retained earnings | -146,829 | -145,157 | -141,574 | -141,079 | -139,168 |
| TOTAL | $2,531 | $4,006 | $6,595 | $6,796 | $482 |
| Total Liabilities And Equity | $4,089 | $6,852 | $8,805 | $8,951 | $3,037 |